Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Over the course of a year of monthly meetings, the CLL Bloodline will teach the BASICS needed to understand CLL, bring news, help with the acronyms and new vocabulary, and offer
Ask the Doctor Question: My mother’s CLL has now relapsed after receiving chemo in 2019. Is Imbruvica the only solution to this or there is any other option? Answer: There are many
Ask the Doctor Question: My IgHV results indicate the following: Hypermutated IgHV2-5.02 2% difference What do the numbers after the IgHV mean (the 2-5.02)? What does the 2% difference mean? Answer: Based on
Question: My wife has CLL and went through only one round of chemotherapy. Between 3-4 weeks thereafter, she developed a rash. The on-call doctor prescribed prednisone and she responded in the
Ask the Doctor Question: I had four successive adverse “anaphylactoid” reactions to rituximab, (as part of a Fludarabine-Rituximab protocol here in Vancouver, Canada) before that treatment was abandoned. Am I at
In this video, Professor Michael Hallek, M.D., the Director of the Center for Integrated Oncology (CIO) at the University of Cologne, Germany, and the head of the German CLL Study Group (GCLLSG) is interviewed by CLL Society founder and Chief Medical Officer, Dr. Brian Koffman, M.D., a retired family physician and a CLL patient. This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020.
This is my report from the third day of ASH 2021, the 63rd American Society of Hematology Annual Conference and Exhibition, this year a hybrid meeting held in Atlanta, Georgia, and virtually around the world.
Welcome back to day two of ASH 2021, the 63rd American Society of Hematology Annual Conference and Exhibition, this year a hybrid meeting held in Atlanta, Georgia and virtually around the world.
Ibrutinib and Venetoclax have as we like to say at the CLL Society orthogonal or complementary mechanisms of action. Ibrutinib inhibits chronic lymphocytic leukemia or CLL cells’ proliferation and gets the cancer cells out of their protective niches in the nodes and bone marrow and into the blood stream where they are easier to kill.
One click to our most popular content.
